Matilde Sinibaldi
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: July 08, 2026
Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.
Journal: Translational oncology
Published: May 18, 2026
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: September 09, 2025
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.
Journal: Nature medicine
Published: August 19, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: March 01, 2025
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.
Journal: Blood advances
Published: February 10, 2025
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Journal: Journal of hematology & oncology
Published: July 11, 2024
Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 06, 2024
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Journal: Nature medicine
Published: February 09, 2024
Humoral and cellular immune response after mRNA SARS-CoV-2 vaccine in children on treatment for cancer: A pilot observational study.
Journal: Heliyon
Published: July 31, 2023
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2023
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Journal: The New England journal of medicine
Published: April 05, 2023
Last Updated: 09/26/2026